Getting a safety notice about a medication you take is unsettling. That is where a small group of Canadians are right now. Health Canada has asked doctors not to start any new patients on TAVNEOS while it re-examines the evidence behind its approval. Here is the key nuance in this TAVNEOS review. It is not a sign the drug suddenly started harming people, but a question about the trustworthiness of the data used to approve it. Those are very different situations, and the difference changes what you should do.
What triggered this drug safety review?
The trigger is the Phase 3 ADVOCATE trial. Phase 3 means the large, near-final human trial a drug must clear before approval, and ADVOCATE was the main study Health Canada relied on. Questions have emerged about how reliable its data is, so the regulator opened a drug safety review to decide whether those doubts change the drug’s benefit-risk profile, the running judgment of whether its benefits still outweigh its risks. It is alerting clinicians through MedEffect, its drug-safety communication system.
Which condition does avacopan treat?
TAVNEOS is the brand name, and avacopan is the drug inside it. Approved in Canada in April 2022, it treats a group of rare autoimmune diseases called ANCA-associated vasculitis, where the immune system mistakenly attacks and inflames the body’s own blood vessels, which can damage the kidneys, lungs, and sinuses. It is used alongside standard treatments like glucocorticoids (steroids that calm inflammation), not on its own.
Who is affected if you already live with ANCA-associated vasculitis?
ANCA-associated vasculitis is genuinely rare, and the drug is reserved for severe, active disease, so it was never widely prescribed. Health Canada is clear on one point, so read it twice. If you already take it, do not stop on your own. The guidance is aimed at prescribers, asking them to hold off on new starts, not to pull current patients off. If you are on it and anxious, call the doctor who prescribed it.
How does post-market surveillance protect you after approval?
Approval leans on trial data from the manufacturer, but it is not the finish line. Post-market surveillance, the ongoing monitoring of a medication once real patients use it, exists so new doubts, even years later, can trigger a fresh look. An approval can be revisited when better information appears. Whether this TAVNEOS review changes anything will depend on what Health Canada finds, and no timeline has been given.
Common questions about the review
Should you stop taking TAVNEOS because of the review?
No. Health Canada has specifically advised patients not to stop on their own. The TAVNEOS review is directed at prescribers and asks them to hold off on starting new patients, not to take current ones off the drug. If you have concerns, raise them with the provider who prescribed it before you change anything.
What is the ADVOCATE trial?
The ADVOCATE trial is the Phase 3 study that supported the drug’s approval for ANCA-associated vasculitis. Health Canada is reviewing questions about the reliability of that trial’s data to decide whether they affect the drug’s benefit-risk profile in Canada. The regulator has not publicly detailed the concerns.
How do you report a side effect?
Health Canada collects reports through its MedEffect Canada program, and both patients and healthcare professionals can submit one. Reporting serious or unexpected reactions helps the regulator keep watch on a medication after it reaches the market. Your pharmacist or doctor can help you file the report.
The bottom line
If you take this drug, or live with a condition like ANCA-associated vasculitis, the useful move is not to panic and not to guess. It is to book a conversation with the specialist who knows your case. Finding a rheumatologist or specialist near you is straightforward at medimap.ca, and the Health Hub (medimap.ca/hub) has more on making sense of health headlines like this.
General information, not medical advice, and not a substitute for your own provider. Do not start or stop any medication based on this article.
Find an allergy or specialist clinic near you? Search through Medimap — no referral needed.
Search clinics →